Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06448572

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. (EXLIBRIS)

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy

Sponsor: Exeliom Biosciences

Interventions EXL01

Updated 4 times since 2024 Last updated: Sep 24, 2025 Started: Jul 16, 2024 Primary completion: Oct 1, 2028 Completion: Oct 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Non-Small Cell Lung Cancer and is currently actively recruiting participants. Exeliom Biosciences leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE1/PHASE2
Jan 2025 — Oct 2025 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Exeliom Biosciences
University Hospital, Lille

Data source: University Hospital, Lille

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lille, France